Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
39.15 HKD | +1.56% | +16.17% | -8.42% |
Apr. 17 | Innovent Appoints Dr. Nageatte Ibrahim as the Oncology Chief Medical Officer | CI |
Apr. 02 | Hutchmed endometrial cancer treatment application accepted for review | AN |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Sales forecast by analysts have been recently revised upwards.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- Based on current prices, the company has particularly high valuation levels.
- The company appears highly valued given the size of its balance sheet.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-8.42% | 7.99B | B- | ||
-4.66% | 87.53B | A- | ||
+2.63% | 40.42B | A- | ||
-21.76% | 29.48B | B- | ||
+55.32% | 25.43B | A | ||
-14.78% | 15.59B | C | ||
-18.49% | 11.49B | B- | ||
-15.61% | 11.1B | D+ | ||
-44.02% | 11.3B | B | ||
+4.94% | 8.75B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 1801 Stock
- Ratings Innovent Biologics, Inc.